Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance.

BACKGROUND Various types of pathologic mechanisms in multiple sclerosis (MS) can alter magnetic resonance imaging (MRI) signals, and the appearance of remyelinated lesions on MRI is largely unknown. OBJECTIVE To describe the MRI appearance of remyelinated lesions in MS. DESIGN Comparison of postmortem MRI findings with histopathologic findings. SETTING Brain donations from a general community. Patients Magnetic resonance images from 36 rapid autopsies yielded 161 areas that could be matched with histologic characteristics, including 149 focal T2-weighted abnormalities, with a range of signal intensities on T1-weighted images. In a subset of 49 lesions, magnetization transfer ratio could be determined. MAIN OUTCOME MEASURES An observer blinded to the MRI findings assessed the presence of remyelination using light microscopic criteria; in 25 areas, in situ hybridization was used to assess the presence of oligodendrocytes expressing proteolipid protein messenger RNA. RESULTS Remyelinated areas were found in 67 lesions (42%): partial remyelination was present in 30 lesions (19%), whereas 37 lesions (23%) were fully remyelinated. Remyelinated lesions contained enhanced numbers of oligodendrocytes containing proteolipid protein messenger RNA. All areas with remyelination shown histopathologically were hyperintense on T2-weighted images. Strong hypointensity on T1-weighted images was significantly associated (chi2 = 29.8, P<.001) with demyelinated and partially remyelinated lesions compared with fully remyelinated lesions. The magnetization transfer ratio of remyelinated lesions (mean [SD], 27.6% [41%]) differed (F = 46.3, P<.001) from both normal-appearing white matter (35.2% [32%]) and demyelinated lesions (22.3% [48%]). CONCLUSIONS Remyelinated lesions return an abnormal signal on T2-weighted images. Both T1-weighted images and magnetization transfer ratio may have (limited) additional value in separating lesions with and without remyelination.

[1]  Hans Lassmann,et al.  Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation? , 1999, The Journal of experimental medicine.

[2]  F. Barkhof.  The clinico‐radiological paradox in multiple sclerosis revisited , 2002, Current opinion in neurology.

[3]  F. Barkhof,et al.  Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.

[4]  P. Sminia,et al.  Expression of transforming growth factor (TGF)-beta1, -beta2, and -beta3 isoforms and TGF-beta type I and type II receptors in multiple sclerosis lesions and human adult astrocyte cultures. , 1999, Journal of neuropathology and experimental neurology.

[5]  B. Trapp,et al.  NG2-Positive Oligodendrocyte Progenitor Cells in Adult Human Brain and Multiple Sclerosis Lesions , 2000, The Journal of Neuroscience.

[6]  J. Whisnant,et al.  IV immunoglobulin does not reverse established weakness in MS , 2000, Neurology.

[7]  R. Rudick,et al.  Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. , 2002, The New England journal of medicine.

[8]  C. Raine,et al.  Multiple Sclerosis: Remyelination in Acute Lesions , 1993, Journal of neuropathology and experimental neurology.

[9]  G. Nahler,et al.  Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis , 1997, The Lancet.

[10]  C. Dijkstra,et al.  Induction of nitric oxide synthase in multiple sclerosis lesions , 1997 .

[11]  F. Barkhof,et al.  Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis , 1992, Annals of neurology.

[12]  J. Caillé,et al.  Early structural changes in acute MS lesions assessed by serial magnetization transfer studies , 1998, Neurology.

[13]  H. Lassmann,et al.  In situ hybridization with digoxigenin-labeled probes: sensitive and reliable detection method applied to myelinating rat brain , 2004, Acta Neuropathologica.

[14]  Hans Lassmann,et al.  Monocyte/macrophage differentiation in early multiple sclerosis lesions , 1995, Annals of neurology.

[15]  F. Barkhof,et al.  Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. , 1998, AJNR. American journal of neuroradiology.

[16]  Hans Lassmann,et al.  Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology , 1997, Annals of neurology.

[17]  P. Valk,et al.  Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. , 2000 .

[18]  Imaging of remyelination , 1997, Multiple sclerosis.

[19]  H. Lassmann,et al.  Histopathological characterization of magnetic resonance imaging-detectable brain white matter lesions in a primate model of multiple sclerosis: a correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus). , 1998, The American journal of pathology.

[20]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[21]  G. Wolswijk.  Chronic Stage Multiple Sclerosis Lesions Contain a Relatively Quiescent Population of Oligodendrocyte Precursor Cells , 1998, The Journal of Neuroscience.

[22]  N. Scolding.  Therapeutic strategies in multiple sclerosis. II. Long-term repair. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[23]  D. McFarlin,et al.  A novel candidate autoantigen in a multiplex family with multiple sclerosis: prevalence of T-lymphocytes specific for an MBP epitope unique to myelination , 1993, Journal of Neuroimmunology.

[24]  C. V. Jensen,et al.  Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis , 1998, Neurology.

[25]  B Quesson,et al.  In vivo evaluation of remyelination in rat brain by magnetization transfer imaging , 2000, Journal of the Neurological Sciences.

[26]  W. Brück,et al.  Oligodendrocytes in the early course of multiple sclerosis , 1994, Annals of neurology.

[27]  C. Lucchinetti,et al.  A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions , 2001, Annals of neurology.

[28]  À. Rovira,et al.  Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images. , 1999, AJNR. American journal of neuroradiology.

[29]  H. Hartung,et al.  Patients with active relapsing‐remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: Implications for remyelination , 2000, Annals of neurology.

[30]  Remyelination in multiple sclerosis , 1979, Annals of neurology.

[31]  W. Brück,et al.  Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. , 2000, Brain : a journal of neurology.

[32]  G. Wolswijk.  Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis. , 2000, Brain : a journal of neurology.

[33]  B. Scheithauer,et al.  A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. , 1999, Brain : a journal of neurology.

[34]  Moses Rodriguez,et al.  Spontaneous and induced remyelination in multiple sclerosis and the theiler's virus model of central nervous system demyelination , 1995, Microscopy research and technique.

[35]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[36]  H. Lassmann,et al.  Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. , 2000, The American journal of pathology.

[37]  F. Barkhof,et al.  The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis , 1999, Neurology.

[38]  F Barkhof,et al.  Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. , 2001, Brain : a journal of neurology.